Evidence map›Paper›PMID 31506868›Full record

ReviewSeminars in immunopathology2019

Molecular determinants for the polarization of macrophage and osteoclast.

Dengbao Yang, Yihong Wan

Abstract readReview
In one paragraph

Review in Seminars in immunopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dengbao YangDepartment of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Yihong WanDepartment of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. yihong.wan@utsouthwestern.edu.

Funding

Context-Dependent Effects of PARP Inhibitors on Breast Cancer Bone MetastasisR01CA229487 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI KRAUS, WILLIAM LEE · 2018 to 2023
$1.8M
Novel Mechanisms of Cancer Bone MetastasisR01CA236802 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI WAN, YIHONG · 2019 to 2020
$741k
NCI NIH HHS R01 CA229487NCI NIH HHS R01 CA236802
6 · The paper itself

Abstract

Emerging evidence suggest that macrophage and osteoclast are two competing differentiation outcomes from myeloid progenitors. In this review, we summarize recent advances in the understanding of the molecular mechanisms controlling the polarization of macrophage and osteoclast. These include nuclear receptors/transcription factors such as peroxisome proliferator-activated receptor γ (PPARγ) and estrogen-related receptor α (ERRα), their transcription cofactor PPARγ coactivator 1-β (PGC-1β), metabolic factors such as mitochondrial complex I (CI) component NADH:ubiquinone oxidoreductase iron-sulfur protein 4 (Ndufs4), as well as transmembrane receptors such as very-low-density-lipoprotein receptor (VLDLR). These molecular rheostats promote osteoclast differentiation but suppress proinflammatory macrophage activation and inflammation, by acting lineage-intrinsically, systemically or cross generation. These findings provide new insights to the understanding of the interactions between innate immunity and bone remodeling, advancing the field of osteoimmunology.

Indexed as

AnimalsBiomarkersBone and BonesERRalpha Estrogen-Related ReceptorHumansImmunomodulationMacrophage ActivationMacrophagesOsteoclastsOsteogenesisOsteoprotegerinPPAR gammaRANK LigandReceptor Activator of Nuclear Factor-kappa BReceptors, EstrogenReceptors, LDLBiomarkersERRalpha Estrogen-Related ReceptorOsteoprotegerinPPAR gammaPPARGC1B protein, humanRANK LigandReceptor Activator of Nuclear Factor-kappa BReceptors, EstrogenReceptors, LDLRNA-Binding ProteinsVLDL receptorBoneERRαMacrophageNdufs4OsteoclastOsteoimmunologyPGC-1βPPARγVLDLR

Identifiers

PMID31506868
PMCPMC6815265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.